Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 3/20 | 0.50 |
| ▸ | DYRK1A | Q13627 | 6/20 | 0.47 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.45 |
| ▸ | CLK1 | P49759 | 5/20 | 0.44 |
| ▸ | CLK4 | Q9HAZ1 | 5/20 | 0.44 |
| ▸ | DYRK1B | Q9Y463 | 5/20 | 0.44 |
| ▸ | DYRK3 | O43781 | 3/20 | 0.44 |
| ▸ | CLK2 | P49760 | 3/20 | 0.44 |
| ▸ | CLK3 | P49761 | 3/20 | 0.44 |
| ▸ | DYRK2 | Q92630 | 3/20 | 0.44 |
| ▸ | DYRK4 | Q9NR20 | 3/20 | 0.44 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.44 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.43 |
| ▸ | PRKCI | P41743 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13136914 | 0.88 | DYRK1A (0.59) | CYP2A6DYRK1AFGFR1CLK1CLK4 | |
| SCHEMBL541566 | 0.86 | HDAC1 (0.58) | CYP2A6FGFR1HDAC1HDAC8ALDH1A1 | |
| SCHEMBL13137075 | 0.83 | DYRK1A (0.54) | DYRK1AFGFR1IP6K1PRKCI | |
| SCHEMBL5695722 | 0.82 | DYRK1A (0.47) | DYRK1ACLK1CLK4DYRK1BDYRK3 | |
| SCHEMBL13931440 | 0.79 | HDAC1 (0.50) | CYP2A6FGFR1HDAC1HDAC8ALDH1A1 | |
| SCHEMBL13136913 | 0.78 | HDAC1 (0.51) | CYP2A6DYRK1AHDAC1HDAC8ALDH1A1 | |
| SCHEMBL5695756 | 0.78 | HDAC1 (0.48) | CYP2A6FGFR1HDAC1HDAC8ALDH1A1 | |
| SCHEMBL29408444 | 0.78 | HDAC1 (0.42) | CYP2A6DYRK1AFGFR1HDAC1HDAC8 | |
| SCHEMBL13136930 | 0.77 | HDAC1 (0.41) | CYP2A6DYRK1AHDAC1HDAC8IP6K1 | |
| SCHEMBL25941136 | 0.76 | DYRK1A (0.45) | DYRK1ACLK1CLK4DYRK1BDYRK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340539-A1 | IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1, AND/OR CLK4 | PERHA PHARMACEUTICALS (FR) | 2025-11-06 | — | — | US | disclosed |
| WO-2025128848-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | VIGIL NEUROSCIENCE, INC. (US) | 2025-06-19 | — | — | WO | disclosed |
| EP-4422753-A1 | IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 | Perha Pharmaceuticals (FR) | 2024-09-04 | — | — | EP | disclosed |
| CN-114929690-B | Novel heterocyclic derivatives having cardiomyocyte proliferative activity for the treatment of heart disease | 同济大学 | 2023-05-05 | — | — | CN | disclosed |
| WO-2023072966-A1 | IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 | PERHA PHARMACEUTICALS (FR) | 2023-05-04 | — | — | WO | disclosed |
| EP-4173675-A1 | IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 | Perha Pharmaceuticals (FR) | 2023-05-03 | — | — | EP | disclosed |
| US-20230025301-A1 | Novel Heterocyclic Derivatives with Cardiomyocyte Proliferation Activity for Treatment of Heart Diseases | TONGJI UNIVERSITY (CN) | 2023-01-26 | — | — | US | disclosed |
| US-20230025301-A1 | Novel Heterocyclic Derivatives with Cardiomyocyte Proliferation Activity for Treatment of Heart Diseases | TONGJI UNIVERSITY (CN) | 2023-01-26 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-20220324878-A1 | IMIDAZOLIDIN-2-ONE COMPOUNDS AS PRMT5 MODULATORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2022-10-13 | — | — | US | disclosed |
| US-20060247233-A1 | Thiazoles inhibitors of the alk-5 receptor | SMITHKLINE BEECHAM CORPORATION | 2006-11-02 | — | — | US | disclosed |
| EP-1660494-A2 | THIAZOLES AS INHIBITORS OF THE ALK-5 RECEPTOR | SMITHKLINE BEECHAM CORPORATION (US) | 2006-05-31 | — | — | EP | disclosed |
| EP-1656367-A1 | 4- (HETEROCYCLYL- FUSED PHENYL)- 3- (PHENYL OR PYRID -2- YL) PYRAZOLES AS INHIBITORS OF THE ALK-5- RECEPTOR | SmithKline Beecham Corporation (US) | 2006-05-17 | — | — | EP | disclosed |
| WO-2005082901-A1 | NOVEL CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-09-09 | — | — | WO | disclosed |
| WO-2004111036-A1 | 4- (HETEROCYCLYL- FUSED PHENYL)- 3- (PHENYL OR PYRID -2- YL) PYRAZOLES AS INHIBITORS OF THE ALK-5- RECEPTOR | SMITHKLINE BEECHAM CORPORATION (US) | 2004-12-23 | — | — | WO | disclosed |
| WO-2004111046-A2 | THIAZOLES AS INHIBITORS OF THE ALK- 5 RECEPTOR | SMITHKLINE BEECHAM CORPORATION (US) | 2004-12-23 | — | — | WO | disclosed |
| EP-1140944-B1 | EPOTHILONE DERIVATIVES AND THEIR USE AS ANTITUMOR AGENTS | NOVARTIS AG (CH) | 2003-08-27 | — | — | EP | disclosed |
| US-6387927-B1 | WATER SOLUBILITY | NOVATIS AG (CH) | 2002-05-14 | — | — | US | disclosed |
| EP-1140944-A1 | EPOTHILONE DERIVATIVES AND THEIR USE AS ANTITUMOR AGENTS | Novartis AG (CH) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000037473-A1 | EPOTHILONE DERIVATIVES AND THEIR USE AS ANTITUMOR AGENTS | NOVARTIS AG (CH) | 2000-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230025301-A1 | Novel Heterocyclic Derivatives with Cardiomyocyte Proliferation Activity for Treatment of Heart Diseases | TNNI3, TNNT2, MKI67 | CYP2A6 1169/4885DYRK1A 3319/4885FGFR1 83/4885 |
| US-20060247233-A1 | Thiazoles inhibitors of the alk-5 receptor | SMAD3, ALK, SMAD2 | CYP2A6 4378/4885DYRK1A 459/4885FGFR1 24/4885 |
| US-20220324878-A1 | IMIDAZOLIDIN-2-ONE COMPOUNDS AS PRMT5 MODULATORS | PRMT5, PRMT1, PRMT7 | CYP2A6 3810/4885DYRK1A 2690/4885FGFR1 4213/4885 |
| US-20250340539-A1 | IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1, AND/OR CLK4 | CLK1, CLK2, CLK3 | CYP2A6 4388/4885DYRK1A 20/4885FGFR1 1358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.